Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2025-04-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
第九届董事会第四十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 40th meeting of the 9th Board of Directors of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results, and specific decisions made regarding the cancellation of a shareholder meeting agenda item related to the election of an independent director candidate. The document is not a full report but an official announcement of board decisions. It does not contain financial statements or detailed management discussion, nor is it a call transcript or regulatory certification. It fits the category of Board/Management Information (MANG) as it relates to board meeting resolutions and changes in board candidate nominations.
2025-04-17 Chinese
关于孙公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Dongbei Pharmaceutical Group Co., Ltd. regarding its subsidiary obtaining a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, approval, and impact on the company. The document is short (1277 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory event. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-04-16 Chinese
关于控股股东一致行动人增持公司股份计划的进展情况暨权益变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement about the progress of a shareholding increase by the controlling shareholder and its concerted parties. It includes specific shareholding percentages before and after the transaction, details of the share purchase plan, loan support for the share purchase, and compliance with relevant securities laws and regulations. The document does not contain financial statements or earnings data but focuses on changes in major shareholding and related disclosures. This matches the definition of a Major Shareholding Notification (MRQ). The document length is 2626 characters, which is consistent with a detailed announcement rather than a full financial report. Therefore, the appropriate classification is MRQ with high confidence.
2025-04-15 Chinese
详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "详式权益变动报告书" which translates to a "Detailed Equity Change Report" for Northeast Pharmaceutical Group Co., Ltd. It details the change in shareholding by the controlling shareholder and related parties, including the number of shares before and after the change, the method of acquisition (centralized bidding), the purpose of the equity change, funding sources, and impact analysis on the company. It also includes detailed information about the shareholders, their financials, and legal compliance. The document is comprehensive and focused on shareholding changes rather than financial results, management changes, or other corporate events. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is lengthy (15,000 characters) and contains substantive detail, not just an announcement or a brief notice, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is MRQ with high confidence.
2025-04-15 Chinese
关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary receiving a drug registration certificate from the national drug regulatory authority. It contains no financial statements, no management discussion of financial results, no earnings data, and no detailed report content. The document is short (1304 characters) and serves as an official announcement of a regulatory approval event. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or insider dealing report. The content is regulatory in nature, announcing a material event related to product registration. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-04-09 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2024 by Northeast Pharmaceutical Group Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, their identification standards, and remediation status. The content focuses on internal control evaluation, audit opinions, and compliance with internal control regulations. It does not contain full financial statements or comprehensive financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not a brief announcement or a certification letter but a detailed report on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. The document length is under 5,000 characters but contains substantive evaluation content, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-02 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.